Diabetic nephropathy: evidence for renoprotection and practice.
Mogensen
C E
CE
Department of Endocrinology and Diabetes, Arhus Kommune Hospital, Arhus University of Hospital, Norrebrogade, DK-8000 Arhus C, Denmark. cem@afdm.au.dk
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000419:Albuminuria / Q000188:drug therapy; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use; D001713:Biphenyl Compounds; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000517:prevention & control; D003928:Diabetic Nephropathies / Q000188:drug therapy*; D004232:Diuretics / Q000627:therapeutic use; D005919:Glomerular Filtration Rate / Q000187:drug effects; D015433:Glomerulonephritis, Membranous / Q000517:prevention & control; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D013777:Tetrazoles / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D002121:Calcium Channel Blockers; D004232:Diuretics; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D013777:Tetrazoles; C081643:candesartan